5 / 6
Page 31
Der Pharmacia Sinica
ISSN: 0976-8688
Eurosc i con Conference on
Medicinal Chemistry
and Biosimilars
M a r c h 2 5 - 2 6 , 2 0 1 9
B u d a p e s t , H u n g a r y
Medicinal Chemistry & Biosimilars 2019
A
n important way the immune system copes wih foreign substances in
the body, is making large numbers of antibodies. Antigens are molecules
that are able to stimulate an immune response. Each antigen has distinct
surface features, or epitopes, causing specific responses (Goodman&Gilman’s
The Pharmacological Basis of Therapeutics, 12th Edition). Antibodies
(immunoglobins) are proteins produced by B cells of the immune system
in response to exposure to antigens. The term monoclonal antibody means
that the man-made antibody is synthesized from cloned immune cells, and
the identical monoclonal antibody produced binds to one type of antigen.
Polyclonal antibodies are synthesized from different immune cells and the
antibodies produced bind to multiple antigens. The monoclonal antibodies are
present in themarket for a long time. Their indications and use are continuing to
expand. Since monoclonal antibodies have been approved for the treatment of
various diseases like chronic lymphocytic leukemia, ovarian cancer and other
solid tumors, rheumatoid arthritis, ovarian cancer, Chron’s disease, Plague
Psoriasis, Psoriatic Arthritis, Ankylosing Spondilitis etc (www.medicinenet.
com, Basic&Clinical Pharmacology, Lange 14th Edition) the incidence of these
drugs’ adverse effects and the cost is growing. If monoclonal antibodies are
compared with chemotherapy drugs, they have fewer serious side effects. As
a result, their adverse effects continue to constitute an important problem. I
will talk about the prominent side effects and the cost of the therapy. I will also
discuss with the audience the future of monoclonal antibody treament.
Biography
Hakkı Zafer Guney is a medical doctor and professor of
pharmacology. He has completed his medical training in
Ankara University Medical School, and speciality training in Gazi
University Medical School, Ankara. Beyond being a professor
of Pharmacology, he is also the president of the society of
biotechnological drugs (BIYILDER) in Turkey since 2018. He
has a company on drug R&D (RD Consultancy Ltd.) in Ankara.
He has several publications and citations in international and
national journals. He has also been serving as an Editorial
Board Member and referee in several international journals.
He is into several fields (clinical trials, pharmacovigilance,
pharmacoeconomics) of clinical pharmacology.
zaferguney@yahoo.comMonoclonal antibodies: their adverse effects and costs
H Zafer Guney, Ozlem Celik Aydin and Demet Kasim
Gazi University Medical School, Turkey
H Zafer Guney et al., Der Pharmacia Sinica 2019, Volume:10
DOI: 10.21767/0976-8688-C1-002